Ukai Rinzo, Hashimoto Kunihiro, Nakayama Hirofumi, Iwamoto Toshiyuki
Department of Urology, JR Hiroshima Hospital, Hiroshima.
Department of Pathology and Laboratory Medicine, JR Hiroshima Hospital, Hiroshima.
Jpn J Clin Oncol. 2017 May 1;47(5):447-452. doi: 10.1093/jjco/hyx012.
Lymphovascular invasion (LVI) in high-grade clinical T1 bladder cancer is usually considered a poor prognostic factor, but it is often difficult to achieve correct staging of T1 bladder cancer and diagnose the presence of LVI because of the inadequacy of conventional transurethral resection specimens. The aims of this study were to evaluate the prognostic value of LVI in patients with correctly staged high-grade pathological T1 (pT1) bladder cancer who initially underwent transurethral resection in one piece (TURBO).
Eighty-six high-grade pT1 bladder cancer patients who underwent TURBO were enrolled. Risk of tumor understaging was avoided by examining the vertical resection margin of the TURBO specimen. Immunohistochemical staining using D2-40 and CD31 was performed to confirm LVI. We examined the association of LVI with other clinicopathological factors and the impact of LVI on progression-free survival and cancer-specific survival.
The median follow-up period was 49 months (range, 6-142). In all patients, the tumors were accurately staged as pT1 at initial TURBO. LVI was detected in 15 patients (17%) and was significantly associated with tumor growth pattern (P = 0.001). Multivariate analysis identified LVI as the only independent predictor for reduced progression-free survival (HR, 4.48; 95% CI, 1.45-13.90; P = 0.009) and cancer-specific survival (HR, 4.35; 95% CI, 1.17-16.24; P = 0.029).
The presence of LVI in TURBO specimens independently predicts poor clinical outcomes in patients with high-grade pT1 bladder cancer. This information may help urologists to counsel their patients when deciding whether to choose a bladder-preserving strategy or radical cystectomy.
高级别临床T1期膀胱癌中的淋巴管浸润(LVI)通常被认为是一个不良预后因素,但由于传统经尿道切除术标本的不足,往往难以实现T1期膀胱癌的正确分期并诊断LVI的存在。本研究的目的是评估LVI在最初接受整块经尿道切除术(TURBO)的正确分期的高级别病理T1(pT1)期膀胱癌患者中的预后价值。
纳入86例行TURBO的高级别pT1期膀胱癌患者。通过检查TURBO标本的垂直切缘避免肿瘤分期过低的风险。使用D2-40和CD31进行免疫组织化学染色以确认LVI。我们研究了LVI与其他临床病理因素的关联以及LVI对无进展生存期和癌症特异性生存期的影响。
中位随访期为49个月(范围6 - 142个月)。在所有患者中,肿瘤在初次TURBO时被准确分期为pT1。15例患者(17%)检测到LVI,且与肿瘤生长模式显著相关(P = 0.001)。多变量分析确定LVI是无进展生存期降低(HR,4.48;95% CI:1.45 - 13.90;P = 0.009)和癌症特异性生存期降低(HR,4.35;95% CI:1.17 - 16.24;P = 0.029)的唯一独立预测因素。
TURBO标本中LVI的存在独立预测高级别pT1期膀胱癌患者的不良临床结局。该信息可能有助于泌尿外科医生在决定是否选择保膀胱策略或根治性膀胱切除术时为患者提供咨询。